July 30 Amgen Inc, which is attempting
to buy Onyx Pharmaceuticals Inc to add to its cancer
drug offerings, on Tuesday reported higher-than-expected second-
quarter profit as sales of many of its drugs rebounded from a
disappointing first quarter.
Most of Amgen's higher profile products had sales that
exceeded Wall Street estimates, and the world's largest
biotechnology company raised its full-year earnings forecast.
Amgen posted a net profit of $1.26 billion, or $1.65 per
share, compared with a profit of $1.26 billion, $1.61 per share,
a year ago
Excluding special items, Amgen earned $1.89 per share.
Analysts on average expected $1.74, according to Thomson Reuters